Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease
Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease
复制标题
DOI：
10.1016/j.nut.2011.06.004
复制
发表时间：
2012-03-01
期刊：
影响因子：
4.4
通讯作者：
Lin, Ping-Ting
中科院分区：
文献类型：
--
作者：
Lee, Bor-Jen;Huang, Yi-Chia;Lin, Ping-Ting
目的：本研究旨在探讨补充辅酶Q10对冠心病患者氧化应激和抗氧化酶活性的影响。将通过心导管检查确定为一条主要冠状动脉至少狭窄50%或接受经皮腔内冠状动脉成形术的患者（n = 51）随机分配到安慰剂组（n = 14）或两个补充辅酶Q10的组之一（60 mg/d，n = 19 [Q10-60组]; 150 mg/d，n = 18 [Q10-150组]）。干预12 wk。每4 wk检测患者血浆辅酶Q10浓度、丙二醛（MDA）和抗氧化酶（过氧化氢酶（CAT）、超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶）活性。辅酶Q10-150干预后血浆辅酶Q10浓度显著升高（P < 0.01）。Q10-150组第4周MDA水平显著低于基线水平（P = 0.03）。第8周时，Q10-150组的MDA水平显著低于安慰剂组（P = 0.03）。在抗氧化酶活性方面，第12周时，Q10-150组受试者的CAT（P = 0.03）和SOD（P = 0.03）活性显著高于安慰剂组。血浆辅酶Q10浓度与MDA（r =-0.35，P = 0.02）、CAT（r = 0.43，P = 0.01）和SOD活性（r = 0.39，P = 0.01）呈显著相关。血浆辅酶Q10/总胆固醇比值与SOD活性呈显著正相关（r = 0.39，P = 0.02）。血浆辅酶Q10/低密度脂蛋白比值与CAT（r = 0.35，P = 0.04）和SOD（r = 0.45，P = 0.01）活性呈显著正相关。结论：补充辅酶Q10 150 mg可降低冠心病患者的氧化应激水平，提高抗氧化酶活性。高剂量辅酶Q10补充剂（> 150 mg/d）可促进CAD患者快速和持续的抗氧化作用。(C)2012 Elsevier Inc. All rights reserved.
Objective: The purpose of this study was to investigate the effect of coenzyme Q10 supplementation on oxidative stress and antioxidant enzyme activity in patients with coronary artery disease (CAD).Methods: This was an intervention study. Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery or receiving percutaneous transluminal coronary angioplasty (n = 51) were randomly assigned to the placebo group (n = 14) or one of the two coenzyme Q10-supplemented groups (60 mg/d, n = 19 [Q10-60 group]; 150 mg/d, n = 18 [Q10-150 group]). Intervention was administered for 12 wk. Patients' blood samples were analyzed every 4 wk for plasma coenzyme Q10 concentrations, malondialdehyde (MDA), and antioxidant enzyme (catalase [CAT], superoxide dismutase [SOD], glutathione peroxidase) activity.Results: Forty-three subjects with CAD completed intervention study. Plasma coenzyme Q10 concentration increased significantly after coenzyme the Q10-150 intervention (P < 0.01). The MDA levels were significantly lower than baseline in the Q10-150 group at week 4 (P = 0.03). The Q10-150 group had significantly lower MDA levels than the placebo group at week 8 (P = 0.03). With respect to antioxidant enzyme activity, subjects in the Q10-150 group had significantly higher CAT (P = 0.03) and SOD (P = 0.03) activity than the placebo group at week 12. The plasma coenzyme Q10 concentration was significantly correlated with MDA levels (r = -0.35, P = 0.02) and CAT (r = 0.43, P = 0.01) and SOD activity (r = 0.39, P = 0.01). The ratio of plasma coenzyme Q10 to total cholesterol was significantly correlated with SOD activity (r = 0.39, P = 0.02). The ratio of plasma coenzyme Q10 to low-density lipoprotein was significantly correlated with CAT (r = 0.35, P = 0.04) and SOD (r = 0.45, P = 0.01) activity. However, there was no relation between coenzyme Q10 concentration and glutathione peroxidase activity.Conclusion: Coenzyme Q10 supplements at a dose of 150 mg can decrease oxidative stress and increase antioxidant enzyme activity in patients with CAD. A higher dose of coenzyme Q10 supplements (> 150 mg/d) might promote rapid and sustainable antioxidation in patients with CAD. (C) 2012 Elsevier Inc. All rights reserved.